Flow cytometric analysis of single pMHCI-IgG binding and pMHCI delivery to hIGF-1R+ NIH3T3 and MCSP+ UCLA-SO-M14 cells target cells at different concentrations.

Slides:

Advertisements

Similar presentations

HMGA2 is a SUMOylation target.

Advertisements

DNA content flow cytometric histograms of propidium iodide–stained A549 cells. DNA content flow cytometric histograms of propidium iodide–stained A549.

Selinexor combines with immune checkpoint blockade to slow B16F10 melanoma tumor growth. Selinexor combines with immune checkpoint blockade to slow B16F10.

Expression of immune checkpoint molecules on leukocytes and tumor cells at baseline and in response to selinexor. Expression of immune checkpoint molecules.

HDAC3, but not HDAC2 is in complex with tau protein.

FL cells are dependent on BCL6 in a NOTCH2-dependent manner.

Percentage of proteins identified in envelope membrane extracts according to the purification method and the number of transmembrane domains. Percentage.

NM-3 induces p21 levels and down-regulation of Cdk2 activity.

Expression of SYCE2 inhibits the interaction of HP1α with H3K9me3.

Overexpression of HGF decreases MET protein levels.

Lapatinib reduces IGF-I signaling in trastuzumab-resistant cells.

ABCG2-K86M shows a markedly reduced surface expression.

A, IC50 dose–response curves of SYD985, T-DM1, and ADC isotype control in all USC cell lines tested in vitro (i.e., HER2 3+ cell lines, P =

BEZ235 induces MAPK signaling in a FOXO3A-dependent manner.

Accumulation of ubiquitinated MDM2 following PN treatment requires the PIKK ATM. A, Western blots of nuclear extract proteins from ZR-75-1 cells treated.

The sesquiterpene lactone PN up-regulates MDM2 and p53 proteins.

Biochemical characterization and localization of EGFRΔ768.

Quantification of NMT knockdown.

GA blocks HIF activity and reduces HIF target expression.

A, IGFBP-3 knockdown via siRNA using real-time qRT-PCR analysis.

Immunohistochemical detection of 8-OHdG by use of the 1F7 monoclonal antibody in oligomer-treated PC3 prostate cancer cells. a, control untreated peripheral.

Cytotoxic activity of HER2-lytic hybrid peptide.

Diagnostic plots of the TGI PKPD model fitted to the A677 TGI data.

A, ATP production by PC3 prostate cancer cells after treatment with oligonucleotide/Lipofectin complexes. a, ATP production by PC3 prostate cancer cells.

EGCG inhibits cell survival and growth of EFT cell lines but not of HBMECs. A, dose-responsive curves of fractional survival of EFT cells (TC32 and TC71)

A, cytotoxicity induced on HER2 3+ USC (ARK-2), HER2 0/1+ USC (ARK-4), and ARK-2/ARK-4 cocultures with 1 μg/mL of SYD985, T-DM1, and ADC isotype control.

Identification of NSC as a FADD-kinase inhibitor.

B7-1 and PD-1 compete for binding to PD-L1.

MSLN-targeted RITs in TNBC in vitro.

Mapping the Pirh2 and p73 interaction sites.

Interaction of MAPJD with E-box sequence of the RIOK1 gene.

NF-kB binds to the NF-κB binding site immediately adjacent to the AT-rich regulatory region. NF-kB binds to the NF-κB binding site immediately adjacent.

Consequences of ICAM-1 expression modulation on the lysis of T1 and G1 cells. Consequences of ICAM-1 expression modulation on the lysis of T1 and G1 cells.

CIN85 interacts with PHD2. CIN85 interacts with PHD2. A, Endogenous PHD2 was immunoprecipitated (IP) with CIN85 antibody from MDA-MB-231, BT-549, and Hs.

Analysis of thermal stability and aggregation properties before and after disulfide stabilization of the pMHCI complex. Analysis of thermal stability and.

Protein purity and integrity after protein A affinity and SEC

Lamellarin D induces cell death through a Fas-independent pathway.

Effect of G9a on the expression of GSH synthesis enzymes.

Induction of cell death in prostate cancer cells by SAHA and ZOL

The differential susceptibility to CTL-induced lysis does not involve Melan-A antigen expression. The differential susceptibility to CTL-induced lysis.

HLA-A*0201 restriction of SSX2-derived p stimulated CD8+ T-cells.

Curcumin suppresses the expression of antiapoptotic proteins in multiple myeloma cells. Curcumin suppresses the expression of antiapoptotic proteins in.

Src expression in a panel of human TCC cell lines.

Characterization of the complex formed at the Fra-1 RCE1.

KPT-9274 shows specificity for attenuation of PAK4 targets preferentially in RCC cells. KPT-9274 shows specificity for attenuation of PAK4 targets preferentially.

PHF10 acts as a transcriptional repressor.

Expression of XCR1 in normal ovarian surface epithelium and the IOSE and borderline EOC cell lines. Expression of XCR1 in normal ovarian surface epithelium.

Expression of Her2 and drug efflux proteins in parental and resistant cell models. Expression of Her2 and drug efflux proteins in parental and resistant.

Binding and antiproliferative effects of ANG4043 and anti-HER2 mAbs on tumor cells. Binding and antiproliferative effects of ANG4043 and anti-HER2 mAbs.

Synergistic cytotoxicity of 17AAG and TNF treatment in human lung cancer cell lines. Synergistic cytotoxicity of 17AAG and TNF treatment in human lung.

FACS analyses of the inhibitory effect induced by mixed docetaxel, gefitinib, and cyclopamine on EGF plus SHHNp–stimulated PC3 cells. FACS analyses of.

Incorporation of the TSTA system into a single plasmid.

Flow cytometric analysis of ROS production in oligonucleotide-treated PC3 prostate cancer cells as demonstrated by the oxidation of H2DCF → DCF and HE.

Effect of coapplication of dexrazoxane and doxorubicin on DSB formation, TOP2A protein level, and apoptosis. Effect of coapplication of dexrazoxane and.

A, P causes G2-M arrest with apoptosis in asynchronous population of PC-3 when exposed to 1.5 and 5 μmol/L P for various time points. A, P

Interaction of Cdx1 and Cdx2 with the putative Cdx-binding sites of the human DSC2 promoter. Interaction of Cdx1 and Cdx2 with the putative Cdx-binding.

Effects of EGCG on the anchorage-independent growth of EFT cells.

IGF-II antibodies inhibited IGF-II-induced phosphorylation of IGF-IR and insulin receptor (IR) in the breast cancer MCF-7 cells. IGF-II antibodies inhibited.

PTPH1 depends on its catalytic activity to increase ER nuclear accumulation and to enhance breast cancer sensitivity to TAM. A, effects of PTPH1 and PTPH1/DA.

Changes in signal transduction pathway induced by gefitinib.

Activation of multiple RTKs in chondrosarcoma cells.

AR is transnitrosylated by HSP90.

SAHA blocks IR-induced increase of RAD51 protein in MM cells.

Amino acid residues in the PD-L1 IgV domain involved in PD-1 and/or B7-1 binding. Amino acid residues in the PD-L1 IgV domain involved in PD-1 and/or B7-1.

In the presence of human monocytes, estradiol increased breast cancer cell dissemination to the periphery via CCL2 and CCL5. In the presence of human monocytes,

CPGL is a growth suppressor in pancreatic cancer cell lines.

Effect of SFN on the total activity and protein expression of HDACs in JB6 P+ cells. Effect of SFN on the total activity and protein expression of HDACs.

Effects of NMT siRNAs on MARCKS and c-Src.

Time course of NMT knockdown.

Expression of CAR, endogenous TCR, and target-cell receptors.

Presentation transcript:

Flow cytometric analysis of single pMHCI-IgG binding and pMHCI delivery to hIGF-1R+ NIH3T3 and MCSP+ UCLA-SO-M14 cells target cells at different concentrations. Flow cytometric analysis of single pMHCI-IgG binding and pMHCI delivery to hIGF-1R+ NIH3T3 and MCSP+ UCLA-SO-M14 cells target cells at different concentrations. A, binding of anti-IGF-1R normal bivalent control antibody without pMHCI-fusion (column 1), single CMV pMHCI-monovalent anti-IGF-1R IgG (column 2), single CMV pMHCI-bivalent anti-IGF-1R IgG (column 3), single EBV pMHCI-monovalent anti-IGF-1R IgG (column 4), and nonbinding single CMV pMHCI-bivalent DP47 IgG (column 5). Antibody/fusion protein concentration is indicated on the left. B, HLA-A2 complexes detected on the cell surface of MCSP+ HLA-A2− UCLA-SO-M14 cells after binding of single CMV pMHCI-anti-MCSP IgG in concentrations of 25 nmol/L to 0.5 nmol/L. Gray, isotype control and secondary antibody; black, test antibody or fusion protein and secondary antibody. Martina Schmittnaegel et al. Mol Cancer Ther 2016;15:2130-2142 ©2016 by American Association for Cancer Research